Showing 10,961 - 10,980 results of 11,110 for search '(( 59 ((0 decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (teer decrease)) ))', query time: 0.76s Refine Results
  1. 10961

    Table1_Trp-574-Leu and the novel Pro-197-His/Leu mutations contribute to penoxsulam resistance in Echinochloa crus-galli (L.) P. Beauv..docx by Penglei Sun (18343673)

    Published 2024
    “…The whole-plant dose–response testing of E. crus-galli to penoxsulam confirmed the evolution of moderate-level resistance in two populations, JL-R (9.88-fold) and HLJ-R (8.66-fold), and a high-level resistance in AH-R (59.71-fold) population. …”
  2. 10962

    Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE<sup>-/-</sup> mice by Julian Jehle (586001)

    Published 2018
    “…This was accompanied by a significant increase in infiltrating macrophages within the atherosclerotic vessel wall (0.33 ± 0.02 vs. 0.27 ± 0.01; n = 13–14; p = 0.0076). …”
  3. 10963

    HSP-4/BiP is required for the normal structure and barrier function of the cuticle in adults and alae formation in dauers. by Ji Zha (3386177)

    Published 2019
    “…Staining was performed as previously described [<a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3000196#pbio.3000196.ref059" target="_blank">59</a>]. …”
  4. 10964

    Identification of druggable small molecule antagonists of the <i>Plasmodium falciparum</i> hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway... by Monique R. Heitmeier (6686069)

    Published 2019
    “…WU-1 also directly competed for N-[2-[2-[2-[(N-biotinylcaproylamino)ethoxy)ethoxyl]-4-[2-(trifluoromethyl)-3H-diazirin-3-yl]benzoyl]-1,3-bis(mannopyranosyl-4-yloxy)-2-propylamine (ATB-BMPA) binding and inhibited the transport of D-glucose with an IC<sub>50</sub> of 5.9 ± 0.8 μM in liposomes containing purified PfHT. …”
  5. 10965

    Graphical summary describing the signaling pathways potentially involved in Emo effects in nematodes. by Jürgen Krücken (225269)

    Published 2021
    “…This shows that activation of SLO-1 [<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1009682#ppat.1009682.ref059" target="_blank">59</a>,<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1009682#ppat.1009682.ref060" target="_blank">60</a>] is the major effect leading to Emo-induced paralysis as indicated by bold arrows. …”
  6. 10966
  7. 10967

    The Distribution of Stable NMJ Microtubule Bundles Marked by the MAP1B-like Protein Futsch Is Altered in <i>spastin</i> Mutant Larvae by Nina Tang Sherwood (126)

    Published 2013
    “…Futsch staining is restored in most terminal boutons of <i>spin-GAL4</i>- or <i>Elav-GS-GAL4-</i>rescued larvae, with only 20% ± 3.7% and 19% ± 5.9% of boutons, respectively, showing no staining (<i>p</i> = 0.09 compared to <i>WCS</i>). …”
  8. 10968

    Supplementary material: Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atr... by Cong Zhu (1859428)

    Published 2024
    “…</li></ul><p dir="ltr"><b>Aim:</b> Nusinersen, administered by intrathecal injection at a dose of 12 mg, is indicated across all ages for the treatment of spinal muscular atrophy (SMA). …”
  9. 10969

    Data_Sheet_1_Secular trends in the epidemiologic patterns of peripheral artery disease and risk factors in China from 1990 to 2019: Findings from the global burden of disease study... by Wei Gong (112494)

    Published 2022
    “…The age-specific incidence significantly increased in individuals aged 40–44, 45–49, 50–54, 55–59, and 60–64 years groups but decreased in 70–74, 75–79, and 80–84 years groups. …”
  10. 10970

    <i>Borassus flabellifer</i> Linn haustorium methanol extract mitigates fluoride-induced apoptosis by enhancing Nrf2/Haeme oxygenase 1 –dependent glutathione metabolism in intestina... by Joice Tom Job (10813835)

    Published 2021
    “…The total polyphenols and total flavonoids present in BHE were estimated to be 39.67 ± 5.14 mg gallic acid equivalent/g extract and 8.59 ± 0.74 mg quercetin equivalent. In cultured intestinal epithelial cells (IEC-6), sodium fluoride exposure-induced apoptosis mediated through antioxidant enzyme inhibition and subsequent oxidative damages. …”
  11. 10971

    Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer by Justin C. Brown (185942)

    Published 2018
    “…Over six months, significant decreases in CTCs were observed in the low-dose (−1.34±0.34; <i>P</i><0.001) and high-dose (−1.18±0.40; <i>P</i> = 0.004) exercise groups, whereas no significant change was observed in the control group (−0.59±0.56; <i>P</i> = 0.292). …”
  12. 10972

    Data_Sheet_1_Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2.docx by Christian Klemann (3779056)

    Published 2019
    “…Cohort analysis extended to all 35 previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50 patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred in 44%. …”
  13. 10973

    Table_1_Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2.xlsx by Christian Klemann (3779056)

    Published 2019
    “…Cohort analysis extended to all 35 previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50 patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred in 44%. …”
  14. 10974

    Image_4_The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma.tif by Ben George (64738)

    Published 2021
    “…Patients with decreasing/stable CA 19-9 during treatment experienced longer survival than patients who experienced an increase in CA 19-9 levels [1L: 10.9 months (10.5 – 11.3) vs. 5.4 months (5.1 – 5.9), p < 0.0001; 2L: 8.2 months (7.7 – 8.5) vs. 4.3 months (4.1 – 4.7), p < 0.001; 3L: 7.5 months (6.6 – 9.2) vs. 3.7 months (3.4 – 4.3), p < 0.001].…”
  15. 10975

    Image_5_The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma.tif by Ben George (64738)

    Published 2021
    “…Patients with decreasing/stable CA 19-9 during treatment experienced longer survival than patients who experienced an increase in CA 19-9 levels [1L: 10.9 months (10.5 – 11.3) vs. 5.4 months (5.1 – 5.9), p < 0.0001; 2L: 8.2 months (7.7 – 8.5) vs. 4.3 months (4.1 – 4.7), p < 0.001; 3L: 7.5 months (6.6 – 9.2) vs. 3.7 months (3.4 – 4.3), p < 0.001].…”
  16. 10976

    Image_3_The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma.tif by Ben George (64738)

    Published 2021
    “…Patients with decreasing/stable CA 19-9 during treatment experienced longer survival than patients who experienced an increase in CA 19-9 levels [1L: 10.9 months (10.5 – 11.3) vs. 5.4 months (5.1 – 5.9), p < 0.0001; 2L: 8.2 months (7.7 – 8.5) vs. 4.3 months (4.1 – 4.7), p < 0.001; 3L: 7.5 months (6.6 – 9.2) vs. 3.7 months (3.4 – 4.3), p < 0.001].…”
  17. 10977

    Image_1_The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma.tif by Ben George (64738)

    Published 2021
    “…Patients with decreasing/stable CA 19-9 during treatment experienced longer survival than patients who experienced an increase in CA 19-9 levels [1L: 10.9 months (10.5 – 11.3) vs. 5.4 months (5.1 – 5.9), p < 0.0001; 2L: 8.2 months (7.7 – 8.5) vs. 4.3 months (4.1 – 4.7), p < 0.001; 3L: 7.5 months (6.6 – 9.2) vs. 3.7 months (3.4 – 4.3), p < 0.001].…”
  18. 10978

    Image_2_The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma.tif by Ben George (64738)

    Published 2021
    “…Patients with decreasing/stable CA 19-9 during treatment experienced longer survival than patients who experienced an increase in CA 19-9 levels [1L: 10.9 months (10.5 – 11.3) vs. 5.4 months (5.1 – 5.9), p < 0.0001; 2L: 8.2 months (7.7 – 8.5) vs. 4.3 months (4.1 – 4.7), p < 0.001; 3L: 7.5 months (6.6 – 9.2) vs. 3.7 months (3.4 – 4.3), p < 0.001].…”
  19. 10979

    Image 1_Relationship between triglyceride glucose-body mass index baselines and variation with future cardiovascular diseases risk in the middle-aged and elderly individuals.jpeg by Junpeng Qiao (11726521)

    Published 2025
    “…After adjusting for potential confounding factors, compared to participants with consistently low TyG-BMI levels, those with moderate TyG-BMI levels and a slowly increasing trend had an HR of 1.27 (95% CI 1.10-1.47), while those with the highest TyG-BMI levels and a slowly decreasing trend had an HR of 1.52 (95% CI 1.26-1.83).…”
  20. 10980

    Image 2_Relationship between triglyceride glucose-body mass index baselines and variation with future cardiovascular diseases risk in the middle-aged and elderly individuals.jpeg by Junpeng Qiao (11726521)

    Published 2025
    “…After adjusting for potential confounding factors, compared to participants with consistently low TyG-BMI levels, those with moderate TyG-BMI levels and a slowly increasing trend had an HR of 1.27 (95% CI 1.10-1.47), while those with the highest TyG-BMI levels and a slowly decreasing trend had an HR of 1.52 (95% CI 1.26-1.83).…”